FindMyKOL
Clinical trialNCT06163508Enrolling, by, invitationObservational

A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells

NCT06163508 is an observational study sponsored by University of Texas Southwestern Medical Center. As of 21 Nov 2026, it is enrolling by invitation only. It studies Q-Cells® in Transverse Myelitis. The registry lists an enrollment of 9 participants at 1 site in 1 country. The registry lists a start date of 12 Dec 2023 and a primary completion date of 31 Dec 2035.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06163508
FieldValue
Registry IDNCT06163508
StatusEnrolling by invitation
Study typeObservational study
Lead sponsorUniversity of Texas Southwestern Medical Center
Enrollment9
Registered sites1
Countries1
ConditionsTransverse Myelitis
DrugsQ-Cells®
Start12 Dec 2023
Primary completion31 Dec 2035
Study completion31 Dec 2035
Last update posted21 Apr 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is an observational study designed to obtain information on the long-term safety, tolerability, and continued activity of Q-Cells®. The study will follow the participants who previously received Q-Cells® for 10 years. The goal of this observational study is to learn about the long term effects of Q-Cells® in people with transverse myelitis. The main objectives the study is to evaluate the safety of patients who have received Q-Cells®. The secondary goal of the study is to get data about the long-term activity of Q-Cells® over a period of 10 years. Patients will complete exams, lab tests, imaging, and questionnaires to monitor their safety.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Benjamin Greenberg, MD

    University of Texas Southwestern Medial Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Texas, United States1 site
  • the University of Texas Southwestern Medical Center

    Dallas

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Q-Cells®
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06163508

Each answer restates registry values shown on this page.

What is NCT06163508?

NCT06163508 is an observational study sponsored by University of Texas Southwestern Medical Center. It studies Q-Cells® in Transverse Myelitis.

Is NCT06163508 recruiting?

As of 21 Nov 2026, it is enrolling by invitation only.

Who leads NCT06163508?

The registry names Benjamin Greenberg, MD (principal investigator, University of Texas Southwestern Medial Center) as the overall official.

Where does NCT06163508 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06163508 study?

The registered drug and biological interventions are Q-Cells®.

When is NCT06163508 expected to complete?

The registry lists a primary completion date of 31 Dec 2035 and a study completion date of 31 Dec 2035. The sponsor last updated the record on 21 Apr 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.